Skip to Main Content

Paper Details

Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data.
Br J Ophthalmol
9
2018
AMD, AREDS, Age, age-related macular degeneration, nAMD, patient, patients, ranibizumab, unilateral neovascular age-related macular degeneration
Antioxidants, Cost-Benefit Analysis, Dietary Supplements, Humans, Macular Degeneration, Markov Chains, Middle Aged, Models, Economic, United Kingdom, Visual Acuity, Zinc
Author NameAffiliation
Aaron LeeUniversity of Washington
Thomas ButtInstitute of Ophthalmology, University College London
Emily Y ChewDivision of Epidemiology and Clinical Research, National Institutes of Health
Elvira Agr??nDivision of Epidemiology and Clinical Applications, National Eye Institute
Traci E ClemonsEMMES Corporation
Catherine EganInstitute of Ophthalmology, University College London
Catherine EganMoorfields Eye Hospital
Cecilia S LeeUniversity of Washington
Adnan TufailInstitute of Ophthalmology, University College London
Adnan TufailMoorfields Eye Hospital
  • 1 - 10

Datasets

Release 1.2